

Luis Querol

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4449619/publications.pdf>

Version: 2024-02-01

102
papers

4,797
citations

117625

34
h-index

106344

65
g-index

113
all docs

113
docs citations

113
times ranked

4024
citing authors

#	ARTICLE	IF	CITATIONS
1	Long-lasting treatment effect of rituximab in MuSK myasthenia. <i>Neurology</i> , 2012, 78, 189-193.	1.1	354
2	Neurofascin IgG4 antibodies in CIDP associate with disabling tremor and poor response to IVIg. <i>Neurology</i> , 2014, 82, 879-886.	1.1	285
3	Antibodies to contactin-1 in chronic inflammatory demyelinating polyneuropathy. <i>Annals of Neurology</i> , 2013, 73, 370-380.	5.3	279
4	Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies: a multicentre observational study. <i>Lancet Neurology</i> , The, 2020, 19, 234-246.	10.2	207
5	Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015, 2, e149.	6.0	205
6	Regional variation of Guillain-Barré syndrome. <i>Brain</i> , 2018, 141, 2866-2877.	7.6	190
7	Autoantibodies in chronic inflammatory neuropathies: diagnostic and therapeutic implications. <i>Nature Reviews Neurology</i> , 2017, 13, 533-547.	10.1	188
8	European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force—Second revision. <i>Journal of the Peripheral Nervous System</i> , 2021, 26, 242-268.	3.1	176
9	Autoantibodies to nodal isoforms of neurofascin in chronic inflammatory demyelinating polyneuropathy. <i>Brain</i> , 2017, 140, 1851-1858.	7.6	167
10	European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force—Second revision. <i>European Journal of Neurology</i> , 2021, 28, 3556-3583.	3.3	153
11	The expanding field of IgG4-mediated neurological autoimmune disorders. <i>European Journal of Neurology</i> , 2015, 22, 1151-1161.	3.3	142
12	Contactin-1 IgG4 antibodies cause paranode dismantling and conduction defects. <i>Brain</i> , 2016, 139, 1700-1712.	7.6	111
13	Specific Contactin N-Glycans Are Implicated in Neurofascin Binding and Autoimmune Targeting in Peripheral Neuropathies. <i>Journal of Biological Chemistry</i> , 2014, 289, 7907-7918.	3.4	98
14	Contactin autoantibodies in myasthenia gravis. <i>Autoimmunity Reviews</i> , 2014, 13, 1003-1007.	5.8	93
15	Altered RIG-I/DDX58-mediated innate immunity in dermatomyositis. <i>Journal of Pathology</i> , 2014, 233, 258-268.	4.5	92
16	Clinical Characteristics of Patients With Double-Seronegative Myasthenia Gravis and Antibodies to Contactin. <i>JAMA Neurology</i> , 2016, 73, 1099.	9.0	90
17	Myasthenia gravis and the neuromuscular junction. <i>Current Opinion in Neurology</i> , 2013, 26, 459-465.	3.6	88
18	Clinical and therapeutic features of myasthenia gravis in adults based on age at onset. <i>Neurology</i> , 2020, 94, e1171-e1180.	1.1	88

#	ARTICLE	IF	CITATIONS
19	PhIP-Seq characterization of autoantibodies from patients with multiple sclerosis, type 1 diabetes and rheumatoid arthritis. <i>Journal of Autoimmunity</i> , 2013, 43, 1-9.	6.5	83
20	Early and Late Neurological Complications after Reduced-Intensity Conditioning Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 1439-1446.	2.0	79
21	COVID-19 vaccine and Guillain-Barré syndrome: let's not leap to associations. <i>Brain</i> , 2021, 144, 357-360.	7.6	77
22	A one-year follow-up study of the Symbol Digit Modalities Test (SDMT) and the Paced Auditory Serial Addition Test (PASAT) in relapsing-remitting multiple sclerosis: an appraisal of comparative longitudinal sensitivity. <i>BMC Neurology</i> , 2015, 15, 40.	1.8	71
23	Anti-neurofascin-155 IgG4 antibodies prevent paranodal complex formation in vivo. <i>Journal of Clinical Investigation</i> , 2019, 129, 2222-2236.	8.2	68
24	Antibodies against peripheral nerve antigens in chronic inflammatory demyelinating polyradiculoneuropathy. <i>Scientific Reports</i> , 2017, 7, 14411.	3.3	62
25	COVID-19-associated ophthalmoparesis and hypothalamic involvement. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2020, 7, .	6.0	62
26	Anti-NF155 chronic inflammatory demyelinating polyradiculoneuropathy strongly associates to HLA-DRB15. <i>Journal of Neuroinflammation</i> , 2017, 14, 224.	7.2	50
27	Antibodies to the Caspr/contactin-1 complex in chronic inflammatory demyelinating polyradiculoneuropathy. <i>Brain</i> , 2021, 144, 1183-1196.	7.6	46
28	Long-term outcome in chronic inflammatory demyelinating polyneuropathy patients treated with intravenous immunoglobulin: A retrospective study. <i>Muscle and Nerve</i> , 2013, 48, 870-876.	2.2	45
29	Pain and the immune system: emerging concepts of IgG-mediated autoimmune pain and immunotherapies. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 177-188.	1.9	44
30	Endothelial progenitor cells in acute ischemic stroke. <i>Brain and Behavior</i> , 2013, 3, 649-655.	2.2	42
31	Serum neurofilament light chain predicts long-term prognosis in Guillain-Barré syndrome patients. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 70-77.	1.9	40
32	Paranodal and other autoantibodies in chronic inflammatory neuropathies. <i>Current Opinion in Neurology</i> , 2015, 28, 474-479.	3.6	39
33	Compromised fidelity of B cell tolerance checkpoints in AChR and MuSK myasthenia gravis. <i>Annals of Clinical and Translational Neurology</i> , 2016, 3, 443-454.	3.7	39
34	Clinical characteristics and outcomes of thymoma-associated myasthenia gravis. <i>European Journal of Neurology</i> , 2021, 28, 2083-2091.	3.3	39
35	Guillain-Barré syndrome after SARS-CoV-2 infection in an international prospective cohort study. <i>Brain</i> , 2021, 144, 3392-3404.	7.6	39
36	Distal hereditary motor neuropathies: Mutation spectrum and genotype-phenotype correlation. <i>European Journal of Neurology</i> , 2021, 28, 1334-1343.	3.3	39

#	ARTICLE	IF	CITATIONS
37	Muscle MRI in a large cohort of patients with oculopharyngeal muscular dystrophy. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 576-585.	1.9	38
38	Analysis of Serum miRNA Profiles of Myasthenia Gravis Patients. <i>PLoS ONE</i> , 2014, 9, e91927.	2.5	35
39	The impact of rituximab infusion protocol on the long-term outcome in anti-MuSK myasthenia gravis. <i>Annals of Clinical and Translational Neurology</i> , 2018, 5, 710-716.	3.7	34
40	Systematic literature review of burden of illness in chronic inflammatory demyelinating polyneuropathy (CIDP). <i>Journal of Neurology</i> , 2021, 268, 3706-3716.	3.6	32
41	Protein array-based profiling of CSF identifies RBPJ as an autoantigen in multiple sclerosis. <i>Neurology</i> , 2013, 81, 956-963.	1.1	31
42	Neurophysiological Evidence of Compensatory Brain Mechanisms in Early-Stage Multiple Sclerosis. <i>PLoS ONE</i> , 2015, 10, e0136786.	2.5	31
43	Autoantibodies in chronic inflammatory demyelinating polyradiculoneuropathy. <i>Current Opinion in Neurology</i> , 2019, 32, 651-657.	3.6	30
44	Diagnostic challenges in chronic inflammatory demyelinating polyradiculoneuropathy. <i>Brain</i> , 2020, 143, 3214-3224.	7.6	30
45	Clinical and Laboratory Features in Anti-NF155 Autoimmune Nodopathy. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2022, 9, .	6.0	30
46	Caveats and Pitfalls of SOX1 Autoantibody Testing With a Commercial Line Blot Assay in Paraneoplastic Neurological Investigations. <i>Frontiers in Immunology</i> , 2019, 10, 769.	4.8	26
47	Neurofilament Light Chain Levels in Anti-NMDAR Encephalitis and Primary Psychiatric Psychosis. <i>Neurology</i> , 2022, 98, .	1.1	25
48	Differences between acute-onset chronic inflammatory demyelinating polyneuropathy and acute inflammatory demyelinating polyneuropathy in adult patients. <i>Journal of the Peripheral Nervous System</i> , 2018, 23, 154-158.	3.1	23
49	Predicting Outcome in Guillain-Barré Syndrome. <i>Neurology</i> , 2022, 98, .	1.1	22
50	Individualized immunoglobulin therapy in chronic immune-mediated peripheral neuropathies*. <i>Journal of the Peripheral Nervous System</i> , 2018, 23, 78-87.	3.1	21
51	Clinical and laboratory features of anti-MAG neuropathy without monoclonal gammopathy. <i>Scientific Reports</i> , 2019, 9, 6155.	3.3	20
52	Head and voice tremor improving with immunotherapy in an anti-NF155 positive CIDP patient. <i>Annals of Clinical and Translational Neurology</i> , 2018, 5, 499-501.	3.7	19
53	Identification of serum microRNAs as potential biomarkers in Pompe disease. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 1214-1224.	3.7	19
54	Novel Immunological and Therapeutic Insights in Guillain-Barré Syndrome and CIDP. <i>Neurotherapeutics</i> , 2021, 18, 2222-2235.	4.4	19

#	ARTICLE	IF	CITATIONS
55	Autoantibody screening in Guillain-Barré syndrome. <i>Journal of Neuroinflammation</i> , 2021, 18, 251.	7.2	19
56	Blood pressure is not associated with haematoma enlargement in acute intracerebral haemorrhage. <i>European Journal of Neurology</i> , 2008, 15, 1085-1090.	3.3	18
57	Antibodies against cell adhesion molecules and neural structures in paraneoplastic neuropathies. <i>Annals of Clinical and Translational Neurology</i> , 2018, 5, 559-569.	3.7	18
58	Clinical and serological features of acute sensory ataxic neuropathy with antiganglioside antibodies. <i>Journal of the Peripheral Nervous System</i> , 2012, 17, 158-168.	3.1	15
59	Antibodies to nodal/paranodal proteins in paediatric immune-mediated neuropathy. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	6.0	15
60	Immune Response and Safety of SARS-CoV-2 mRNA-1273 Vaccine in Patients With Myasthenia Gravis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022, 9, .	6.0	15
61	Polyradiculoneuropathy Associated to Human Herpesvirus 2 in an HIV-1-Infected Patient (Elsberg) <i>Tj ETQq1 1 0.784314 rgBT /Overl</i>	1.7	14
62	Longitudinal study on nerve ultrasound and corneal confocal microscopy in NF155 paranodopathy. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 1061-1068.	3.7	14
63	Chronic inflammatory demyelinating polyneuropathy associated with contactin-1 antibodies in a child. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019, 6, .	6.0	13
64	Absence of antibodies against KIR4.1 in multiple sclerosis: A three-technique approach and systematic review. <i>PLoS ONE</i> , 2017, 12, e0175538.	2.5	12
65	Boundaries of chronic inflammatory demyelinating polyradiculoneuropathy. <i>Journal of the Peripheral Nervous System</i> , 2020, 25, 4-8.	3.1	12
66	Thrombospondin-1 mediates muscle damage in brachio-cervical inflammatory myopathy and systemic sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	6.0	12
67	Carotid thrombosis after in vitro fertilization: a relatively new thrombotic complication in women. <i>British Journal of Haematology</i> , 2008, 141, 897-899.	2.5	11
68	Antibodies against nodo-paranodal proteins are not present in genetic neuropathies. <i>Neurology</i> , 2020, 95, e427-e433.	1.1	11
69	Rituximab in myasthenia gravis: efficacy, associated infections and risk of induced hypogammaglobulinemia. <i>Neuromuscular Disorders</i> , 2022, 32, 664-671.	0.6	11
70	231st ENMC International Workshop: Neuromuscular Disorders, 2018, 28, 178-184.	0.6	10
71	Unique post-exercise electrophysiological test results in a new Andersen-Tawil syndrome mutation. <i>Clinical Neurophysiology</i> , 2011, 122, 2537-2539.	1.5	9
72	Frequency and clinical correlates of anti-nerve antibodies in a large population of CIDP patients included in the Italian database. <i>Neurological Sciences</i> , 2022, 43, 3939-3947.	1.9	9

#	ARTICLE	IF	CITATIONS
73	Perception of Stigma in Patients with Neuromyelitis Optica Spectrum Disorder. Patient Preference and Adherence, 2021, Volume 15, 713-719.	1.8	8
74	Contactin-1 Antibodies Link Autoimmune Neuropathies to Nephrotic Syndrome. SSRN Electronic Journal, 0, , .	0.4	8
75	Excellent Response to Plasma Exchange in Three Patients With Enterovirus-71 Neurological Disease. Frontiers in Neurology, 2019, 10, 548.	2.4	7
76	Electrodiagnosis of Guillain-Barre syndrome in the International GBS Outcome Study: Differences in methods and reference values. Clinical Neurophysiology, 2022, 138, 231-240.	1.5	7
77	Charcotâ€“Marieâ€“Tooth disease due to <i>MORC2</i> mutations in Spain. European Journal of Neurology, 2021, 28, 3001-3011.	3.3	6
78	Serum Contactin-1 in CIDP. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, e1040.	6.0	6
79	Outcome measures and biomarkers in chronic inflammatory demyelinating polyradiculoneuropathy: from research to clinical practice. Expert Review of Neurotherapeutics, 2021, 21, 805-816.	2.8	6
80	Cognitive Performance and Health-Related Quality of Life in Patients with Neuromyelitis Optica Spectrum Disorder. Journal of Personalized Medicine, 2022, 12, 743.	2.5	6
81	Effect of MAPK Inhibition on the Differentiation of a Rhabdomyosarcoma Cell Line Combined With CRISPR/Cas9 Technology: An In Vitro Model of Human Muscle Diseases. Journal of Neuropathology and Experimental Neurology, 2018, 77, 964-972.	1.7	5
82	Study of the effect of anti-rhGAA antibodies at low and intermediate titers in late onset Pompe patients treated with ERT. Molecular Genetics and Metabolism, 2019, 128, 129-136.	1.1	5
83	Autoantibodies in immune-mediated inflammatory neuropathies. Medicina ClÃnica (English Edition), 2019, 153, 360-367.	0.2	4
84	Burden of illness in chronic inflammatory demyelinating polyneuropathy: some clarifications. Journal of Neurology, 2020, 267, 3094-3095.	3.6	4
85	Severe exacerbation of Andersenâ€“Tawil syndrome secondary to thyrotoxicosis. Journal of Human Genetics, 2014, 59, 465-466.	2.3	3
86	Visual pathway demyelination in neurofascin-155 IGG4- positive combined central and peripheral demyelination. Journal of the Neurological Sciences, 2019, 405, 196-197.	0.6	3
87	Multi-centre validation of a flow cytometry method to identify optimal responders to interferon-beta in multiple sclerosis. Clinica Chimica Acta, 2019, 488, 135-142.	1.1	3
88	Autoimmune nodopathies: treatable neuropathies beyond traditional classifications. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 1025-1025.	1.9	3
89	Optic Nerve Demyelination in IgG4 Antiâ€“Neurofascin 155 Antibodyâ€“Positive Combined Central and Peripheral Demyelination Syndrome. Journal of Central Nervous System Disease, 2021, 13, 117957352110399.	1.9	3
90	Impact of Neuromyelitis Optica Spectrum Disorder on Quality of Life from the Patientsâ€™ Perspective: An Observational Cross-Sectional Study. Neurology and Therapy, 2022, 11, 1101-1116.	3.2	3

#	ARTICLE	IF	CITATIONS
91	Absence of pathogenic mutations in CD59 in chronic inflammatory demyelinating polyradiculoneuropathy. PLoS ONE, 2019, 14, e0212647.	2.5	2
92	Autoanticuerpos en neuropatías inflamatorias inmunomediadas. Medicina Clínica, 2019, 153, 360-367.	0.6	2
93	Chronic inflammatory demyelinating polyneuropathy with hypertrophic nerves. Journal of the Peripheral Nervous System, 2021, 26, 227-230.	3.1	1
94	P.14.1 Dysregulation of innate immunity-related genes in Dermatomyositis. Neuromuscular Disorders, 2013, 23, 813.	0.6	0
95	Whole body muscle MRI correlates with muscle function in patients with adult onset Pompe disease. Neuromuscular Disorders, 2015, 25, S188.	0.6	0
96	LIMB-GIRDLE MUSCULAR DYSTROPHY I. Neuromuscular Disorders, 2018, 28, S33.	0.6	0
97	Isotyping paranodal antibodies in inflammatory neuropathies. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, e843.	6.0	0
98	Quantifying the patient's perspective in neuromyelitis optica spectrum disorder: Psychometric properties of the SymptoMScreen questionnaire. PLoS ONE, 2021, 16, e0255317.	2.5	0
99	Impact of neuromyelitis optica spectrum disorder on quality of life: Assessing the patients' perspective. Journal of the Neurological Sciences, 2021, 429, 118844.	0.6	0
100	Autoantibodies in Neuromuscular Disorders. , 2016, , 3-20.		0
101	PB1964 ROLE OF HOMOCYSTEINE AND METHILMALONIC ACID IN NEUROLOGICAL PATHOLOGY. HemaSphere, 2019, 3, 892-893.	2.7	0
102	Professor Isabel Illa (1952 - 2022). Neuromuscular Disorders, 2022, 32, 450.	0.6	0